Does once-daily dosing prevent nephrotoxicity in all aminoglycosides equally?

Clinical Microbiology and Infection

Volumn 6, Issue 7, 2000, Pages 355-360

  Beaucaire, G ^a,b  

^a Dron Hospital   (France)

^b UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFTAZIDIME; CREATININE; GENTAMICIN; IMIPENEM; ISEPAMICIN; NETILMICIN; TOBRAMYCIN;

ADULT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEHYDRATION; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DRUG UPTAKE; HUMAN; HYPOKALEMIA; KIDNEY FUNCTION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; NOTE; PNEUMONIA; PRIORITY JOURNAL; SEPTICEMIA;

EID: 0034236198     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2000.00105.x     Document Type: Article

References (55)

1. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance
2. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration
3. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model
4. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections
5. Aminoglycoside nephrotoxicity-a tale of two transports
6. The pathology of acute renal failure due to interstitial nephritis in man with comments on the role of interstitial inflammation and sex in gentamicin nephrotoxicity
7. Risk factors for aminoglycoside nephrotoxicity
8. Aminoglycoside kinetics and clinical use in renal insufficiency
9. Risk factors for nephrotoxicity in patients treated with aminoglycosides
10. Incidence of and significant risk factors for aminoglycoside-side-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring
11. Once- versus twice-daily amikacin regimen: Efficacy and safety in systemic Gram-negative infections
12. Once-daily gentamicin versus once-daily netilmicin in patients with serious infections-a randomized clinical trial
13. Once daily dosing of aminoglycosides
14. Aminoglycosides: Single or multiple daily dosing? A meta-analysis on efficacy and safety
15. Single or multiple daily doses of aminoglycosides: A meta-analysis
16. Effectiveness and safety of once-daily aminoglycosides: A meta-analysis
17. Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis
18. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses
19. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides
20. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides
21. Single daily dosing of aminoglycosides in immunocompromised adults: A systematic review
22. Risk factors for toxicity in elderly patients given aminoglycosides once daily
23. Comparison: Of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients
24. Comparison of tobramycin nephrotoxicity in young adult and aged female rats
25. Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients
26. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats
27. Recovery of cortical phospholipidoses and necrosis after acute gentamicin loading in rats
28. Choice of drug and dosage regimen: Two important risk factors for aminoglycoside nephrotoxicity
29. Serum level monitoring of antimicrobial drugs. A review
30. Practicalities of once-daily aminoglycoside dosing
31. Once versus thrice daily gentamicin in patients with serious infections
32. Pharmacologic factors associated with gentarnicin nephrotoxicity in rabbits
33. Nephrotoxicity of gentamicin and tobramycin given once daily or continuously in dogs
34. The influence of dosage regimen on experimental gentamicin nephrotoxicity: Dissociation of peak serum levels from renal failure
35. The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity and antibacterial efficacy in a rat model of subcutaneous abscess
36. The effect of dosing strategy on kidney cortical accumulation of aminoglycosides in rats
37. Insights into the renal handling of aminoglycosides: A guideline for prevention of nephrotoxicity
38. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin
39. Editorial response: Single daily dosing of aminoglycosides-a concept whose time has not yet come
40. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer
41. Clinical strategies for the reduction of aminoglycoside nephrotoxicity and ototoxicity
42. Early effects of gentamicin, tobramycin and amikacin on the human kidney
43. Inhibition of renal membrane binding and nephrotoxicity of aminoglycosides
44. Relationships between chemical structure and adverse effects of antibacterial and antifungal agents
45. A randomized comparison of the safety and efficacy of once-daily gentamicin or thrice-daily gentamicin in combination with ticarcillin-clavulanate
46. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity
47. Ototoxicity and nephrotoxicity of gentamicin vs netilmicin in patients with serious infections. A randomized clinical trial
48. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients
49. Once-daily aminoglycoside dosing: Impact on requests and costs for therapeutic drug monitoring
50. Pharmacoeconomic impact of once-daily aminoglycoside administration
51. Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia
52. An overview of the safety ofiseparnicin in adults
53. Is it still possible to reduce the incidence of nephrotoxicity of aminoglycosides?
54. Aminoglycoside-induced nephrotoxicity
55. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: A costeffectiveness analysis